By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its retagliptin and metformin compound. This new medication is indicated for improving blood sugar control in adult patients with type 2 diabetes, to be used in conjunction with diet and exercise.
Product Mechanism
The product is a fixed-dose combination of the dipeptidyl peptidase-4 (DPP4) inhibitor retagliptin and metformin. It works through a dual mechanism to achieve a synergistic effect in lowering blood sugar levels.
Market Landscape
Several similar products are already available globally, including MSD’s Janumet, Novartis’ Eucreas, and Takeda’s Kazano. According to EvaluatePharma data, this class of drugs generated combined global sales of USD 1.155 billion in 2024.-Fineline Info & Tech